The high-throughput screening system for inhibitor Mycobacterium tuberculosis compounds based on ATP hydrolysis activity of recombinant protein ClpC1
Keywords:ATPase, ClpC1, High throughput screening system, Mycobacterium tuberculosis, Recombinant protein
The global Tuberculosis (TB) rate continues to increase by 1% per year with the widespread of drug-resistant TB. Therefore, the development and research to find new anti-TB drugs are becoming an extremely urgent mission. To be able to screen lead anti-tuberculosis drugs, currently, researchers have to carry out directly on the cells of Mycobacterium tuberculosis and to be performed in bio-security facilities level 3 or 4, to prevent infection from pathogens. However, our results demonstrated that the screening of anti-TB drug candidates can be implemented in bio-security facilities level 1 laboratory with the Escherichia coli cell extraction and recombinant ClpC1 protein - an integral part of the Mycobacterium tuberculosis genome. We focused on the ATP hydrolysis activity of ClpC1 to create a specific research direction for the high-throughput anti-tuberculosis drug screening system. ClpC1 protein was overexpressed and purified with functionally characterized (93.5 kDa). The steady-state growth of recombinant ClpC1 protein in Luria-Bertani (LB) broth High Salt medium was maintained and stabilized after extraction. The determined ATPase activity of ClpC1 was performed by measuring the released phosphate from the reaction. Ecumicin was chosen to be a control compound with expected ATP hydrolysis activities (Hill coefficient = 1,19 ± 0,217; Kd value = 0,52 ± 0,275). We tested this high throughput screening system with ten anti-TB drugs to evaluate the effectiveness of our screening system. Based on these results, we built a complete high-throughput screening system anti-tuberculosis drug safety and quickly.
Botos I, Melnikov EE, Cherry S, Halatova AGK, Rasulova FS, Tropea JE, Maurizi MR, Rotanova TV, Gustchina A, Wlodawer A (2004) Crystal structure of the AAA+ α domain of E. coli Lon protease at 1.9 Å resolution. Journal of Structural Biology 146, Issues 1–2, pp 113-122.
Bradford MM (1976) A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248-254.
Cali JJ, Niles A, Valley MP, O'Brien MA, Riss TL, Shultz J (2008) Bioluminescent assays for ADMET. Expert Opin Drug Metab Toxicol 4(1):103-20.
Fraga H, Rodriguez B, Bardera A, Cid C, Akopian T, Kandror O, Park A, Colmenarejo G, Lelievre J, Goldberga A (2019) Development of high throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis. Anal Biochem 567: 30–37.
Kim JY (2015) Understanding the biosynthesis and mode of action of ecumicin targeting on ClpC1 of Mycobacterium tuberculosis. Graduate School, Myongji University.
Hoskins JH, Pak M, Maurizi MR, Wickner S (1998) The role of the ClpA chaperone in proteolysis by ClpAP. PNAS 95 (21) 12135-12140.
Kar NP, Sikriwal D, Rath P, Choudhary RK, Batra JK (2008) Mycobacterium tuberculosis ClpC1. Febs J. 275 6149–6158.
Kim KI, Cheong GW, Park SC, Ha JS, Woo KM, Choi SJ, Chung CH (2000) Heptameric ring structure of the heat-shock protein ClpB, a protein-activated ATPase in Escherichia coli. Journal of Molecular Biology 303, Issue 5, pp 655-666.
Lee H, Suh JW (2016) Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1. Journal of Industrial Microbiology & Biotechnology 43, Issue 2–3, pp 205–212.
Loughran S, Bree RT, Walls D (2017) Prurification of Polyhistidine-Tagged Proteins. Protein Chromatography: Methods and Protocols (pp. 275-303).
Martin A, Baker TA, Sauer RT (2008) Protein unfolding by a AAA+ protease is dependent on ATP-hydrolysis rates and substrate energy landscapes. Nat Struct Mol Biol 15, 139- 145.
Nagel M (2011). Purification of His-tag proteins. User manual Protino Ni-TED/IDA Combi Sample.
Pavan ME, Pavan EE, Cairó FM, Pettinari MJ (2016) Expression and refolding of the protective antigen of Bacillus anthracis: A model for high-throughput screening of antigenic recombinant protein refolding. Revista Argentina de Microbiología 48, Issue 1, Pages 5-14.
Sacchettini JC, Rubin EJ, Freundlich JS (2008) Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nature Reviews Microbiology 6, pages 41–52.
Sezonov G, Joseleau-Petit D, D’Ari R (2007) Escherichia coli Physiology in Luria-Bertani Broth. J Bacteriol 189(23): 8746-8749.
Zumla A, Nahid P, Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nature Reviews Drug Discovery 12: 388–404.
Wermuth CG (2006) Possible Alternatives to High‐Throughput Screening. Drug Discovery and Development: Drug Discovery Volume 1, Chapter 7.
World Health Organization (WHO). Global tuberculosis report 2015, 2016, 2017, 2018.
World Health Organization (WHO). Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). 2018.
Worzella T, Larson B (2006) Optimizing Kinase Assays for Ultrahigh-Throughput Profiling Using the Kinase-Glo® Plus Assay. Promega Corporation.